Marketing Plan: Launch of Osamax

4859 Words Dec 4th, 2012 20 Pages
Marketing Plan for the launch of “OSAMAX ”
Current market situation

Nepalese Pharmaceutical market and its marketing practices is complex to understand. With no such specific guidelines and policies from its regulatory body DDA, Nepalese pharmaceuticals feel the gap for visionary support from government. Though the country is self reliant in various categories the chunk of market share is still being enjoyed by foreign and Indian companies due to the lack of specific guidelines. Nepal pharmaceutical Laboratory is going to introduce its new product in the market where its competitors already exists. Osamax competing brands are :
RESTOFOS – Sun Pharmaceuticals – Indian company
OSTEOFOS – Cipla Pharmaceuticals – Indian company
…show more content…
Due to its significant achievement in work system and standardization NPL is the only domestic pharmaceutical company that has been awarded with “FNCCI National excellence award for three consecutive years since 2059 to 2062 and recently been awarded with FNCCI Service excellence award in the year 2067. NPL has also been honored with NICCI excellence award 2003 by Nepalese chamber of commerce and industry.

Technological advancement: NPL is the first company to collaborate with academia for the development of research activities in NPL, NPL has collaborated with Kathmandu University school of science for conducting bioavailability and bioequivalence testing of medicine testing of medicine, NPL has also expanded its QC plant with the name of Nepal Research Foundation in the year 2066 basically for the development of novel drug delivery system and research activities.
NPL holds the pioneer ship to manufacture cardiovascular, psychotropic, anti-diabetic products in Nepal .It is also the first company to manufacture veterinary medicines. There are different divisions within the company. Divisions of NPL | | | Division I | Deals with high value molecules | Molecules that requires doctor prescriptions | Division II | Primary care products | Me too ( push strategy ) | Lapen DIV | Sophisticated molecule | Cardiovascular, diabetic, psychotropic | Vet DIV | Veterinary products | Vet |

Future plans:
NPL is constantly on a move to
Open Document